Detalhe da pesquisa
1.
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma.
Blood
; 2024 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38768337
2.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34269818
3.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289038
4.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
5.
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Ann Hematol
; 100(4): 1065-1077, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33599794
6.
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Blood
; 128(13): 1735-44, 2016 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27516441
7.
Multi-subgroup gene screening using semi-parametric hierarchical mixture models and the optimal discovery procedure: Application to a randomized clinical trial in multiple myeloma.
Biometrics
; 74(1): 313-320, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28498490
8.
Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.
Blood
; 125(24): 3756-9, 2015 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25943786
9.
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
Blood
; 123(16): 2504-12, 2014 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24497533
10.
Enhancing cancer clonality analysis with integrative genomics.
BMC Bioinformatics
; 16 Suppl 13: S7, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26424171
11.
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Blood
; 121(23): 4753-7, 2013 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23603914
12.
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Haematologica
; 100(9): 1214-21, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26022710
13.
Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.
J Immunol
; 190(6): 2966-75, 2013 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23408834
14.
In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.
Genes Chromosomes Cancer
; 53(7): 549-57, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24638926
15.
Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis.
BMC Bioinformatics
; 15 Suppl 11: S9, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25350589
16.
Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing.
BMC Bioinformatics
; 15 Suppl 11: S3, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25350881
17.
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Blood
; 120(8): 1597-600, 2012 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22674807
18.
Prediction of cytogenetic abnormalities with gene expression profiles.
Blood
; 119(21): e148-50, 2012 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-22496154
19.
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
Blood
; 120(10): 2076-86, 2012 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22753872
20.
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Blood Cancer J
; 14(1): 24, 2024 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307865